Invivyd, Inc. - Common Stock (IVVD)
2.1100
+0.8600 (68.80%)
Invivyd, Inc. is a biotechnology company focused on developing innovative therapies to address significant unmet medical needs in the field of infectious diseases
The company primarily concentrates on creating monoclonal antibody treatments designed to prevent and treat viral infections, thereby aiming to improve patient outcomes and enhance public health. With a commitment to leveraging cutting-edge research and development, Invivyd seeks to bring new and effective solutions to the market, ultimately striving to protect populations from the impact of various viral threats.
![](https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp)
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · February 5, 2025
![](https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp)
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session.
Via Chartmill · February 4, 2025
![](https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp)
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Via Chartmill · February 4, 2025
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 4, 2025
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
IVVD stock results show that Invivyd met analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 9, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
IVVD stock results show that Invivyd missed analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 28, 2024
![](https://cdn.benzinga.com/files/images/story/2025/02/04/Palantir-Technologies-Japan-Logo--Tokyo-.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 4, 2025
![](https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp)
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · February 3, 2025
![](https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp)
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via Chartmill · February 3, 2025
![](https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp)
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Via Chartmill · February 3, 2025
![](https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp)
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via Chartmill · February 3, 2025
![](https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp)
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · February 3, 2025
![](https://cdn.benzinga.com/files/images/story/2025/02/03/bz-pharma-briefs.jpeg?width=1200&height=800&fit=crop)
Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.
Via Benzinga · February 3, 2025
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 3, 2025
![](https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp)
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · January 31, 2025
![](https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp)
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · January 27, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/10/Genetic-Research-And-Biotech-Science-Con_0.jpeg?width=1200&height=800&fit=crop)
Invivyd's new data highlights Pemgarda's activity against SARS-CoV-2 XEC and over 75% of variants, with consistent neutralization since Omicron BA.1.
Via Benzinga · January 10, 2025
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 10, 2025
![](https://cdn.benzinga.com/files/images/story/2024/10/30/Stock-market-analysts.png?width=1200&height=800&fit=crop)
Via Benzinga · October 30, 2024
![](https://cdn.benzinga.com/files/images/story/2024/08/21/movers-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · August 21, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
IVVD stock results show that Invivyd missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 14, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/05/image_6.jpg?width=1200&height=800&fit=crop)
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday.
Via Benzinga · April 5, 2024